These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 7687354

  • 1. C-erbB-2 oncogene product expression depends on tumour type and is related to oestrogen receptor and lymph node status in human breast carcinoma.
    Heatley M, Maxwell P, Whiteside C, Toner PG.
    Pathol Res Pract; 1993 Apr; 189(3):261-6. PubMed ID: 7687354
    [Abstract] [Full Text] [Related]

  • 2. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein.
    Looi LM, Cheah PL.
    Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
    McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BM, Carney DN.
    Cancer Res; 1991 Jun 15; 51(12):3296-303. PubMed ID: 1674898
    [Abstract] [Full Text] [Related]

  • 4. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
    Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH.
    Cancer Res; 1989 Apr 15; 49(8):2087-90. PubMed ID: 2564806
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Fernö M, Parwaresch R, Alm P.
    J Pathol; 1999 Jan 15; 187(2):207-16. PubMed ID: 10365096
    [Abstract] [Full Text] [Related]

  • 7. Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer.
    Horak E, Smith K, Bromley L, LeJeune S, Greenall M, Lane D, Harris AL.
    Oncogene; 1991 Dec 15; 6(12):2277-84. PubMed ID: 1685017
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
    Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, Keramopoulos A.
    J Pathol; 1996 May 15; 179(1):31-8. PubMed ID: 8691341
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer.
    Hainsworth PJ, Henderson MA, Stillwell RG, Bennett RC.
    Eur J Surg Oncol; 1991 Feb 15; 17(1):9-15. PubMed ID: 1671658
    [Abstract] [Full Text] [Related]

  • 11. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
    Kommoss F, Colley M, Hart CE, Franklin WA.
    Mol Cell Probes; 1990 Feb 15; 4(1):11-23. PubMed ID: 1969111
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Correlation between histological grade and c-erbB2 oncoprotein overexpression in infiltrating ductal carcinoma of breast.
    Looi LM, Cheah PL, Yap SF.
    Malays J Pathol; 1997 Jun 15; 19(1):35-9. PubMed ID: 10879240
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.
    Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE.
    Cancer Res; 1988 Mar 01; 48(5):1238-43. PubMed ID: 2893663
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immunohistochemical c-erbB-2 protooncogene expression and nuclear DNA content in human mammary carcinoma in situ.
    Schimmelpenning H, Eriksson ET, Pallis L, Skoog L, Cedermark B, Auer GU.
    Am J Clin Pathol; 1992 May 01; 97(5 Suppl 1):S48-52. PubMed ID: 1374218
    [Abstract] [Full Text] [Related]

  • 20. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
    Lodato RF, Maguire HC, Greene MI, Weiner DB, LiVolsi VA.
    Mod Pathol; 1990 Jul 01; 3(4):449-54. PubMed ID: 2170971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.